With endocrine resistance being an obstacle toward effective therapy, the addition of a CDK4/6 inhibitor to endocrine therapy as a combination therapy presents with prolonged PFS and has recently been included as a first line therapy in advanced HR+ BC (226, 228–230) (Figure 3B). This evidence concerns the gene CDK4 and breast cancer.